Alnylam's vutrisiran Phase 3 results suggest slowing ATTR amyloidosis progression, potentially becoming a first-line therapy, with reduced TTR protein levels.
Alnylam Pharmaceuticals shared promising Phase 3 results for vutrisiran, an investigational treatment for ATTR amyloidosis with cardiomyopathy, at the HFSA Annual Scientific Meeting 2024. The data indicate that vutrisiran may slow disease progression and could become a first-line therapy. The drug effectively reduces TTR protein levels, impacting cardiac function. Alnylam plans to submit regulatory applications globally by year-end.
September 29, 2024
3 Articles